InvestorsHub Logo
Followers 1
Posts 132
Boards Moderated 0
Alias Born 01/14/2016

Re: PuuliTuku post# 26035

Friday, 09/23/2016 9:41:57 AM

Friday, September 23, 2016 9:41:57 AM

Post# of 30352
And I am referring to this deal from july:

Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital
$7.0 Million Equity Facility with Existing Long-Term Shareholder
SAN DIEGO, July 06, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI) (the “Company” or “Apricus”), a biopharmaceutical company focusing on the development and commercialization of novel therapeutics to treat areas of unmet medical need, today announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC ("Aspire Capital").

Aspire Capital will complete an initial purchase of 2,531,645 shares of common stock for proceeds of $1.0 million and has committed to purchase up to $6.0 million in additional shares of common stock over the next 24 months at prices based on the market price at the time of each sale. No warrants are associated with this agreement.

“This agreement with Aspire Capital will enable Apricus to sell shares from time-to-time on market-based terms to a committed, long-time investor," said Richard Pascoe, CEO of Apricus. "The Aspire Capital team has been supportive of our strategic re-positioned focus on Vitaros® as an existing shareholder. We intend to use the proceeds from this facility, along with our existing cash and expected Vitaros revenues, for working capital purposes as we work towards a potential U.S. Vitaros approval decision in the first half of 2017.”



PuuliTuku

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SEEL News